CYCN vs. OKYO, OMGA, SLGL, PMN, RNXT, AKTX, IXHL, CGTX, LSTA, and CVM
Should you be buying Cyclerion Therapeutics stock or one of its competitors? The main competitors of Cyclerion Therapeutics include OKYO Pharma (OKYO), Omega Therapeutics (OMGA), Sol-Gel Technologies (SLGL), ProMIS Neurosciences (PMN), RenovoRx (RNXT), Akari Therapeutics (AKTX), Incannex Healthcare (IXHL), Cognition Therapeutics (CGTX), Lisata Therapeutics (LSTA), and CEL-SCI (CVM). These companies are all part of the "pharmaceutical products" industry.
Cyclerion Therapeutics vs.
OKYO Pharma (NASDAQ:OKYO) and Cyclerion Therapeutics (NASDAQ:CYCN) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, dividends, risk, earnings, analyst recommendations, valuation, media sentiment, institutional ownership and community ranking.
Cyclerion Therapeutics received 26 more outperform votes than OKYO Pharma when rated by MarketBeat users. However, 100.00% of users gave OKYO Pharma an outperform vote while only 58.62% of users gave Cyclerion Therapeutics an outperform vote.
OKYO Pharma has a beta of -0.26, meaning that its share price is 126% less volatile than the S&P 500. Comparatively, Cyclerion Therapeutics has a beta of 1.71, meaning that its share price is 71% more volatile than the S&P 500.
OKYO Pharma's return on equity of 0.00% beat Cyclerion Therapeutics' return on equity.
Cyclerion Therapeutics has higher revenue and earnings than OKYO Pharma.
OKYO Pharma presently has a consensus price target of $7.00, indicating a potential upside of 573.08%. Given OKYO Pharma's stronger consensus rating and higher probable upside, analysts clearly believe OKYO Pharma is more favorable than Cyclerion Therapeutics.
3.0% of OKYO Pharma shares are owned by institutional investors. Comparatively, 75.6% of Cyclerion Therapeutics shares are owned by institutional investors. 40.5% of OKYO Pharma shares are owned by insiders. Comparatively, 36.1% of Cyclerion Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
In the previous week, OKYO Pharma had 1 more articles in the media than Cyclerion Therapeutics. MarketBeat recorded 1 mentions for OKYO Pharma and 0 mentions for Cyclerion Therapeutics. Cyclerion Therapeutics' average media sentiment score of 1.00 beat OKYO Pharma's score of 0.00 indicating that Cyclerion Therapeutics is being referred to more favorably in the news media.
Summary
OKYO Pharma beats Cyclerion Therapeutics on 8 of the 14 factors compared between the two stocks.
Get Cyclerion Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for CYCN and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cyclerion Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:CYCN) was last updated on 1/21/2025 by MarketBeat.com Staff
